Oryzon Genomics S.A. Overview
Pro stress-test →Oryzon Genomics is a publicly listed, clinical-stage biopharmaceutical company and a European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches for disorders of the central nervous system (CNS), as well as oncology and hematology. The company leverages proprietary epigenetic platforms to discover and develop innovative therapeutics targeting unmet medical needs.
Strategic Profile
Pro stress-test →The company develops proprietary drug candidates through clinical Phase II, at which point it decides on a case-by-case basis to either keep development in-house or partner or out-license the compound for late stage development and commercialization. The company has a strong intellectual property position and originates and owns all its IP portfolio, created internally through a concerted effort of its functional genomics, medicinal chemistry, preclinical and clinical development teams.
Competitive Landscape
Pro stress-test →Oryzon competes within the broader epigenetics drug development space against other biotech companies focused on histone deacetylase inhibitors and lysine-specific demethylase inhibitors. Roche previously had rights to ORY-1001 but discontinued development and returned rights to Oryzon Genomics. The company's strength lies in its originator position and full IP ownership rather than competing on size or resources.
Industry Context
Oryzon Genomics S.A. operates in Biopharmaceuticals - Epigenetics / Clinical Stage Development.
Key facts
Founded: 2003 · Headquarters: Barcelona, Spain